Background: Some patients with metastatic melanoma live longer when they are treated with combinations of immune-checkpoint inhibitors (1, 2). However, up to 55% of these patients experience high-grade, immune-related adverse events (3–5). In phase 3 trials of these drugs, immune-related adverse events involving the heart affected only 0.19% of patients; fulminant myocarditis was the most serious of these (5).

Objective: To report what we believe to be the first patient to survive fulminant myocarditis induced by immune-checkpoint inhibitors.

中文翻译：

---

免疫检查点抑制剂诱发的恶性心肌炎后的生存

背景：一些转移性黑色素瘤患者接受免疫检查点抑制剂的组合治疗后寿命更长（1、2）。但是，这些患者中多达55％经历了高度的，与免疫相关的不良事件（3-5）。在这些药物的3期试验中，涉及心脏的免疫相关不良事件仅影响0.19％的患者；暴发性心肌炎是其中最严重的（5）。

目的：报告我们认为是免疫检查点抑制剂诱发的暴发性心肌炎首例存活的患者。